Canaccord Genuity Maintains Buy on Cytokinetics (CYTK)

Article Stock Quotes (1) Comments (0)

Canaccord Genuity maintained a Buy rating on Cytokinetics (NASDAQ: CYTK) and lowered its price target to $4.00 (from $6.00).

"We think CK357 (tirasemtiv) Ph1/2 proof-of-concept data in ALS shows unique if early efficacy potential. We also think partner Amgen is committed to developing omecamtiv for heart failure," said analyst Ritu Baral.

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $0.68 yesterday, with a 52 week range of $0.57-$1.29.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Urban Outfitters (URBN) Added to Best Ideas List at Janney Capital on Solid Q1 Results
• Goldman Sachs Upgrades Abbott Labs (ABT) to Buy

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?